Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study

BACKGROUND AND HYPOTHESES: Weight gain and adverse cardiometabolic effects often limit the clinical utility of olanzapine. In ENLIGHTEN-2, combining olanzapine with the opioid receptor antagonist samidorphan (OLZ/SAM) mitigated olanzapine-associated weight gain. These analyses tested the hypothesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Correll, Christoph U, Stein, Evan, Graham, Christine, DiPetrillo, Lauren, Akerman, Sarah, Stanford, Arielle D, Jiang, Ying, Yagoda, Sergey, McDonnell, David, Hopkinson, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Regular Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016392/
https://www.ncbi.nlm.nih.gov/pubmed/36305696
http://dx.doi.org/10.1093/schbul/sbac144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016392/
https://www.ncbi.nlm.nih.gov/pubmed/36305696
http://dx.doi.org/10.1093/schbul/sbac144

Ejemplares similares